Recent Advances of Vaccine Adjuvants for Infectious Diseases

키워드

참고문헌 (51)

1. Fauci, A. S., "Infectious diseases: considerations for the 21st century", Clin. Infect. Dis, 32, pp.675~685 (2001)
2. Leroux-Roels, G., "Unmet needs in modern vaccinology:adjuvants to improve the immune response", Vaccine, 28(Suppl 3), pp.C25~C36 (2010)
3. Chan, E. H., "Global capacity for emerging infectious disease detection", Proc. Natl. Acad. Sci. U. S. A, 107, pp.21701~21706 (2010)
4. WHO Ebola Response Team, "Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections", N. Engl. J. Med, 371, pp.1481~1495 (2014)
5. Riese, P., "Vaccine adjuvants: key tools for innovative vaccine design", Curr. Top. Med. Chem, 13, pp.2562~2580 (2013)
6. Baxter D., "Active and passive immunity, vaccine types, excipients and licensing", Occup. Med. (Lond), 57, pp.552~556 (2007)
7. Reed, S. G., "Key roles of adjuvants in modern vaccines", Nat. Med, 19, pp.1597~1608 (2013)
8. Glenny, A. T., "Immunological notes. XVII–XXIV", J. Pathol. Bacteriol, 29, pp.31~40 (1926)
9. Brewer, J. M., "(How) do aluminium adjuvants work?", Immunol. Lett, 102, pp.10~15 (2006)
10. Lindblad, E. B, "Aluminium adjuvants--in retrospect and prospect", Vaccine, 22, pp.3658~3668 (2004)
11. Glenny, A. T., "The antigenic effect of intravenous injection of diphtheria toxin", J. Pathol. Bacteriol, 28, pp.273~278 (1925)
12. Hutchison, S., "Antigen depot is not required for alum adjuvanticity", FASEB J, 26, pp.1272~1279 (2012)
13. Awate, S., "Mechanisms of action of adjuvants", Front. Immunol, 4, pp.114~ (2013)
14. Marrack, P., "Towards an understanding of the adjuvant action of aluminium", Nat. Rev. Immunol, 9, pp.287~293 (2009)
15. Reed, S. G., "New horizons in adjuvants for vaccine development", Trends Immunol, 30, pp.23~32 (2009)
16. Gupta, R. K., "Aluminum compounds as vaccine adjuvants", Adv. Drug Deliv. Rev, 32, pp.155~172 (1998)
17. O'Hagan, D. T., "The mechanism of action of MF59 - an innately attractive adjuvant formulation", Vaccine, 30, pp.4341~4348 (2012)
18. Podda, A., "The adjuvanted influenza vaccines with novel adjuvants : experience with the MF59-adjuvanted vaccine", Vaccine, 19, pp.2673~2680 (2001)
19. Gasparini, R., "Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects", Int. J. Clin. Pract, 64, pp.432~438 (2010)
20. Calabro, S., "Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes", Vaccine, 29, pp.1812~1823 (2011)
21. O'Hagan, D. T., "The history of MF59(®)adjuvant : a phoenix that arose from the ashes. Expert Rev", Vaccines, 12, pp.13~30 (2013)
22. Morel, S., "Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity", Vaccine, 29, pp.2461~2473 (2011)
23. Brito, L. A., "Designing and building the next generation of improved vaccine adjuvants", J. Control Release, 190, pp.563~579 (2014)
24. Almeida, J. D., "Formation of virosomes from influenza subunits and liposomes", Lancet, 2, pp.899~901 (1975)
25. Moser, C., "Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations", Expert Rev. Vaccines, 6, pp.711~721 (2007)
26. Cusi, M. G., "Applications of influenza virosomes as a delivery system", Hum. Vaccin, 2, pp.1~7 (2006)
27. Medzhitov, R., "Toll-like receptors and innate immunity", Nat. Rev. Immunol, 1, pp.135~145 (2001)
28. Coffman, R. L., "Vaccine adjuvants:putting innate immunity to work", Immunity, 33, pp.492~503 (2010)
29. Gustafson, G. L., "Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity", Res. Immunol, 143, pp.483~488 (1992)
30. Garcon, N., "GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives", Expert Rev. Vaccines, 6, pp.723~739 (2007)
31. Descamps, D., "Safety of human papillomavirus (HPV)-16", 18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials, 2009, pp.5, 332~340
32. Beran, J., "Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients", Expert Opin. Biol. Ther, 8, pp.235~247 (2008)
33. Didierlaurent, A. M., "AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity", J. Immunol, 183, pp.6186~6197 (2009)
34. Krieg, A. M., "Therapeutic potential of Toll-like receptor 9 activation", Nat. Rev. Drug Discov, 5, pp.471~484 (2006)
35. Eng, N. F., "The potential of 1018 ISS adjuvant in hepatitis B vaccines:HEPLISAV review", Hum. Vaccin. Immunother, 9, pp.1661~1672 (2013)
36. Hasegawa, H., "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses", Ther. Clin. Risk Manag, 5, pp.125~132 (2009)
37. Duthie, M. S., "Use of defined TLR ligands as adjuvants within human vaccines", Immunol. Rev, 239, pp.178~196 (2011)
38. Taylor, D. N., "Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response", Vaccine, 30, pp.5761~5769 (2012)
39. Turley, C. B., "Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine(STF2. 4xM2e)in healthy adults", Vaccine, 29, pp.5145~5152 (2011)
40. Morein, B., "Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses", Nature, 308, pp.457~460 (1984)
41. Garcia, A., "An overview of adjuvant formulations and delivery systems", APMIS, 122, pp.257~267 (2014)
42. Lovgren, B. K., "ISCOM technology-based Matrix MTM adjuvant : success in future vaccines relies on formulation. Expert Rev", Vaccines, 10, pp.401~403 (2011)
43. Cummings, J. F., "Recombinant Liver Stage Antigen-1(LSA-1)formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma", IL-2 CD4＋ T cells but does not protect against experimental Plasmodium falciparum infection, 2010, pp.28, 5135~5144
44. Oleszycka, E., "Immunomodulatory properties of the vaccine adjuvant alum", Curr. Opin. Immunol, 28, pp.1~5 (2014)
45. De, G. E., "Alum adjuvanticity:unraveling a century old mystery", Eur. J. Immunol, 38, pp.2068~2071 (2008)
46. O'Hagan, D. T., "Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles", Mol. Med. Today, 3, pp.69~75 (1997)
47. Garcon, N., "Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion", Expert Rev. Vaccines, 11, pp.349~366 (2012)
48. Atmar, R. L., "Adjuvants for pandemic influenza vaccines", Curr. Top. Microbiol. Immunol, 333, pp.323~344 (2009)
49. Schwendener, R. A., "Liposomes as vaccine delivery systems:a review of the recent advances", Ther. Adv. Vaccines, 2, pp.159~182 (2014)
50. Moser, C., "Influenza virosomes as vaccine adjuvant and carrier system", Expert Rev. Vaccines, 12, pp.779~791 (2013)
51. Garcon, N., "Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile", Expert Opin. Biol. Ther, 11, pp.667~677 (2011)

관련 논문AI추천